Caroline Seymour

Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024

The FDA has granted accelerated approval to tarlatamab for the treatment of patients with ES-SCLC with disease progression on or after platinum-based chemotherapy.

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

May 16th 2024

Vepdegestrant plus palbociclib maintained clinical efficacy and safety in patients with pretreated, advanced ER-positive, HER2-negative breast cancer.

Pertuzumab Plus Trastuzumab Surpasses Prespecified Activity Threshold in ERBB2/3-Altered Biliary Tract Cancer

May 15th 2024

Pertuzumab plus trastuzumab produced antitumor activity and a mild adverse effect profile in patients with pretreated biliary tract cancer with ERBB2/3 alterations.

Capecitabine or XELOX Does Not Significantly Improve Efficacy vs PF in Inoperable ESCC

May 15th 2024

Capecitabine or XELOX failed to improve OS at 2 years vs fluorouracil/cisplatin as DCRT in inoperable locally advanced esophageal squamous cell carcinoma.

Salvage Nivolumab/Ipilimumab Following Nivolumab Affords Treatment-Free Survival in RCC

May 11th 2024

Salvage treatment with nivolumab plus ipilimumab following progression on nivolumab alone led to significant treatment-free survival in advanced ccRCC.

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024

Health Canada has approved an sNDA for goserelin acetate 10.8 mg every 12 weeks for ER-positive early breast cancer with a high risk of recurrence or advanced breast cancer.

FDA Approves Trastuzumab-strf for HER2-Overexpressing Breast and Gastric/GEJ Cancer

April 29th 2024

The FDA has approved trastuzumab-strf for HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or GEJ adenocarcinoma.

FDA Grants Fast Track Designation to CTX-009 Plus Paclitaxel for Pretreated Biliary Tract Cancer

April 25th 2024

CTX-009 plus paclitaxel has received FDA fast track designation for pretreated metastatic or locally advanced biliary tract cancer.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer.

FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma

April 12th 2024

The FDA’s ODAC voted that data support the use of minimal residual disease as an end point to support accelerated approval of treatments in multiple myeloma.

Nadofaragene Firadenovec Showcases Sustained Responses in BCG-Unresponsive NMIBC

April 12th 2024

The intravesical gene therapy elicited durable remissions in a high percentage of patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer.

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

April 10th 2024

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

April 9th 2024

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Mirvetuximab Soravtansine Plus Pembrolizumab Makes a Splash in pMMR/MSS FRalpha+ Endometrial Cancer

April 9th 2024

Mirvetuximab soravtansine plus pembrolizumab displays efficacy in recurrent or persistent, FRalpha-positive, pMMR/MSS serous endometrial cancer.

Preliminary Data Hint at PFS Benefit With Personalized Neoantigen Vaccine in Metastatic MSS CRC

April 2nd 2024

Treatment with GRANITE showed early signals of activity following frontline induction chemotherapy in metastatic microsatellite stable colorectal cancer.

Adagrasib Improves PFS, ORR in Previously Treated KRAS G12C–Mutant NSCLC

March 28th 2024

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Amivantamab Plus Chemo Nearly Doubles Time to Treatment Discontinuation, Need for Subsequent Therapy in EGFR Exon 20+ NSCLC

March 20th 2024

Amivantamab plus chemotherapy extended the time to treatment discontinuation and subsequent therapy in EGFR exon 20 insertion–mutated NSCLC.

FDA Accepts BLA Resubmission for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma

March 18th 2024

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

Olaparib Plus Cediranib Falls Short in All-Comers With Platinum-Resistant or Refractory Ovarian Cancer

March 16th 2024

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

NEXT PAGE
PREVIOUS PAGE